Human Cyclin Dependent Kinase Inhibitor 1B (CDKN1B) Protein

Por favor contáctenos para obtener información detallada sobre el precio y disponibilidad.
Description
Human CDKN1B Protein is a recombinant Human protein produced in a Prokaryotic expression system (E. coli).
Documents del producto
Product specifications
Category | Proteins and Peptides |
Immunogen Target | Cyclin Dependent Kinase Inhibitor 1B (CDKN1B) |
Host | E. coli |
Origin | Human |
Conjugation | Unconjugated |
Observed MW | Molecular Weight: Calculated MW: 25.8 kDa Concentration: Prior to lyophilization: 200 µg/ml Sequence Fragment: Met1-Thr198 Tag: N-terminal His tag |
Expression | Recombinant |
Purity | > 90% |
Size 1 | 10 µg |
Size 2 | 50 µg |
Size 3 | 100 µg |
Size 4 | 200 µg |
Size 5 | 500 µg |
Form | Lyophilized To keep the original salt concentration, we recommend reconstituting to the original concentration prior to lyophilization (see Concentration) in ddH2O. If a lower concentration is required, dilute in PBS, pH 7.4. If a higher concentration is required, the product can be reconstituted directly in PBS, pH 7.4, though please note that this will change the overall salt concentration. The stock concentration should be between 0.1-1.0 mg/ml. Do not vortex. |
Tested Applications | WB, SDS-PAGE |
Buffer | Prior to lyophilization: PBS, pH 7.4, containing 0.01% Sarcosyl, 1 mM DTT, 5% Trehalose and Proclin-300. |
Availability | Shipped within 5-7 working days. |
Storage | Store at 2-8 °C for up to one month. Store at -80 °C for up to one year. Avoid repeated freeze/thaw cycles. |
Dry Ice | No |
UniProt ID | P46527 |
Background | Protein CDKN1B |
Status | RUO |
Note | This product is for research use only. Not for human consumption, cosmetic, therapeutic or diagnostic use. |
Descripción
Related Products

Human CDKN1B (Cyclin Dependent Kinase Inhibitor 1B) ELISA Kit
Ver Producto
Mouse CDKN1B (Cyclin Dependent Kinase Inhibitor 1B) ELISA Kit
Ver Producto
CDKN1B antibody
CDKN1B, also named as P27 or KIP1, is a cyclin-dependent kinase inhibitor, which shares a limited similarity with CDK inhibitor CDKN1A/p21. P27 binds to and prevents the activation of cyclin E-CDK2 or cyclin D-CDK4 complexes, and thus controlling cell cycle progression at G1. The degradation of this protein, which is triggered by its CDK dependent phosphorylation and subsequent ubiquitination by SCF complexes, is required for the cellular transition from quiescence to the proliferative state. Downregulation of P27 has been implicated in the progression of several malignancies, including lung cancer, hepatocellular carcinoma, salivary cancer, oral squamous cell carcinomas, and gastric cancer.
Ver Producto